Testing a kidney-protecting drug in sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have sickle cell disease (genotypes HbSS or HbSβ0-thalassemia).
- Your urine must show a moderate amount of protein (albuminuria with UACR between 100 and 2,000 mg/g).
- Your hemoglobin level must be 5.5 g/dL or higher.
- You cannot have diabetes.
- You cannot have an active leg ulcer or a current urinary tract infection.
- You cannot have had a sickle cell crisis or other severe pain event requiring hospitalization in the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called an SGLT2 inhibitor (canagliflozin-like) can help slow kidney disease in people with type 1 diabetes. It may help protect your kidneys if you already have protein in your urine and reduced kidney function.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This study tests two new methods to measure how well your kidneys can handle extra work, called kidney reserve. It might help find early signs of kidney problems in people with sickle cell disease or those who have donated a kidney.
This study collects kidney tissue samples from people with sickle cell disease and healthy volunteers to better understand how sickle cell affects the kidneys. If you have sickle cell disease or a related blood disorder, you may help researchers find new ways to protect kidney function.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
Hear when a new Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.